 ImmunoGen recently gained the accelerated approval of mirvetuximab Elahere for resistant ovarian cancers with high FRA expression. As the first-of-its-kind, Elahere would enjoy strong market demands. Nevertheless, there are significant hurdles to a successful launch. 